We believe this funding from leading investors will help us scale up our ReSOLVE platform while simultaneously driving towards planned investigational new drug (IND) submissions for our three lead programs in 2023.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

100 Beaver St. 202
Waltham, MA 02453
USA

Phone

(514) 397-9517

Website

www.ventustx.com

Email Address

[email protected]

Overview

At Ventus, we are focused on discovering and developing novel therapeutics that target the innate immune system with the goal of addressing autoimmune diseases, inflammatory diseases, and cancer. Guided by a patient-centric ethos, our aim is to rapidly advance multiple drug candidates. Our emerging pipeline focuses on the inflammasome and nucleic acid sensing pathways.

Profile

Social Media

Ventus Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Hao Wu

Chief Executive Officer

Marcelo Bigal

Chief Financial Officer

Zack McNealy

Founder

Richard Flavell

Founder

Judy Lieberman

Founder

Thomas Tuschl

Vice President

Michael Turner

VP - Bus. Development

Daniel Koerwer

VP - R & D

Michael Crackower

Browse more venture capital transactions:

Prev: 2/18/2022: EasyKnock venture capital transaction
Next: 2/18/2022: Arkuda Therapeutics venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary